IRIDEX (NASDAQ:IRIX) Earns Hold Rating from Analysts at StockNews.com

Analysts at StockNews.com assumed coverage on shares of IRIDEX (NASDAQ:IRIX) in a note issued to investors on Sunday. The firm set a “hold” rating on the medical equipment provider’s stock.

IRIDEX Price Performance

Shares of NASDAQ IRIX opened at $1.65 on Friday. The firm has a market cap of $27.45 million, a PE ratio of -2.46 and a beta of 0.82. The business has a 50 day moving average price of $1.70 and a two-hundred day moving average price of $1.81. The company has a quick ratio of 0.85, a current ratio of 1.54 and a debt-to-equity ratio of 0.55. IRIDEX has a fifty-two week low of $1.27 and a fifty-two week high of $3.65.

IRIDEX (NASDAQ:IRIX) last issued its earnings results on Tuesday, November 12th. The medical equipment provider reported ($0.12) EPS for the quarter. The firm had revenue of $11.58 million during the quarter. IRIDEX had a negative return on equity of 192.95% and a negative net margin of 22.79%. During the same period last year, the firm posted ($0.11) EPS.

About IRIDEX

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments.